Asset profile
duvakitug
Monoclonal antibody
Evidence outlook · registrational
Crohn's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2029-05-14.
RELIEVE UCCD (NCT05499130): Randomized, double-blind, placebo-controlled, with the high dose reaching significance (p=.003) and replicating in a Crohn's disease cohort. The low dose was only borderline (p=.050) and the sample size per arm was modest. A well-designed trial with a partial, dose-dependent result is capped at moderate rather than strong. Progressed to Phase 3.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Ulcerative Colitis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
92 competitors in this universe: 7 direct rivals (same mechanism and indication), 1 same-class, 84 same-indication; 59 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Duvakitug: this drug | Phase 3 | Monoclonal antibody | TL1A | ||
| Afimkibart | Phase 3 | Monoclonal antibody | TL1A | ||
| Tulisokibart | Phase 3 | Monoclonal antibody | TL1A | ||
| MT-201 | Phase 2 | Multispecific antibody | TL1A, IL-23 p19 | ||
| SPY002 | Phase 2 | Monoclonal antibody | TL1A | ||
| SSGJ-627 | Phase 2 | Biologic (subtype unspecified) | TL1A | ||
| XmAb942 | Phase 1/2 | Monoclonal antibody | TL1A | ||
| TL-003 | Phase 1 | Multispecific antibody | TL1A, IL-23 p19 | ||
| SPY072 | Phase 2 | — | TL1A | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha | ||
| Adalimumab-Aqvh (Yusimry) | Approved | — | TNF-alpha |
…and 77 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (2)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.